Cowen And Company, LLC Relmada Therapeutics, Inc. Transaction History

Cowen And Company, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$2.17 - $35.84 $330,773 - $5.46 Million	-152,430 Reduced 70.43%	64,011 $223,000
Q3 2022 Nov 14, 2022	SELL	$18.3 - $37.02 $15.6 Million - $31.5 Million	-850,413 Reduced 79.71%	216,441 $8.01 Million
Q2 2022 Aug 05, 2022	SELL	$16.5 - $30.34 $1.61 Million - $2.96 Million	-97,507 Reduced 8.37%	1,066,854 $20.3 Million
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $17 Million - $27.4 Million	1,014,587 Added 677.41%	1,164,361 $31.4 Million
Q4 2021 Feb 14, 2022	SELL	$16.93 - $26.82 $166,912 - $264,418	-9,859 Reduced 6.18%	149,774 $3.37 Million
Q2 2021 Aug 13, 2021	SELL	$29.55 - $39.15 $215,980 - $286,147	-7,309 Reduced 4.38%	159,633 $5.11 Million
Q1 2021 May 04, 2021	BUY	$31.52 - $39.28 $5.26 Million - $6.56 Million	166,942 New	166,942 $5.88 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.